1. Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies.
- Author
-
Dickopf, Steffen, Buldun, Can, Vasic, Vedran, Georges, Guy, Hage, Carina, Mayer, Klaus, Forster, Matthias, Wessels, Uwe, Stubenrauch, Kay-Gunnar, Benz, Jörg, Ehler, Andreas, Lauer, Matthias E., Ringler, Philippe, Kobold, Sebastian, Endres, Stefan, Klein, Christian, and Brinkmann, Ulrich
- Subjects
- *
BISPECIFIC antibodies , *IMMUNOGLOBULINS , *MONONUCLEAR leukocytes , *MOLECULAR size , *ANTIBODY-dependent cell cytotoxicity - Abstract
PACE generates an active TriFab T cell engager from two inactive prodrugs By crosslinking the T cell receptor on T lymphocytes and tumor cells, TCBs induce potent T cell-mediated cytotoxicity at the tumor site ([22]). Keywords: bsAb; immunotherapy; prodrug; T cell engager EN bsAb immunotherapy prodrug T cell engager 495 508 14 04/12/22 20220401 NES 220401 Introduction The therapeutic applicability of numerous antibody derivatives in clinical development is limited by unfavorable properties such as safety or pharmacokinetics ([17]; [38]; [39]). Total antibody-like protein (kappa(+)) was detected by capturing with a biotinylated anti-human kappa light chain Fab (Clone M-1.7.10), coated onto a Streptavidin microtiter plate (SA-MTP, MicroCoat Biotechnologie GmbH, Bernried) and detection was performed with a digoxigenin-labeled anti human Ch1 antibody (Clone M-1.19.31) Biotin-binding antibodies (formed if two prodrugs assemble into a functional
-TriFab) were detected by capturing the antibody with biotinylated albumin, coated to a streptavidin microtiter plate. [Extracted from the article] - Published
- 2022
- Full Text
- View/download PDF